IMMY

IMMY (Immuno-Mycologics, Inc.) is a leading biotechnology company focused on the development and manufacturing of diagnostic solutions for fungal diseases. Based in Norman, Oklahoma, the company is best known for its revolutionary CrAg LFA, a rapid point-of-care test for Cryptococcal antigen that has significantly improved survival rates for HIV/AIDS patients in resource-limited settings. IMMY's extensive portfolio includes assays for Histoplasma, Aspergillus, and Coccidioides, utilizing technologies such as lateral flow, ELISA, and latex agglutination. The company operates as a key partner to global health organizations like the WHO and CDC to expand access to fungal diagnostics worldwide. With a commitment to innovation in mycology, IMMY continues to develop new tools to combat invasive fungal infections.